REG - Avacta Group PLC - Posting of Annual Report and Notice of AGM

AvactaAnnouncement

31/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe5392Qa&default-theme=true

RNS Number : 5392Q  Avacta Group PLC  31 May 2024

 

 

 

31 May 2024

 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

Posting of Annual Report and Notice of AGM

 

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, today announces that its
Annual Report and Accounts for the year ended 31 December 2023 and the Notice
of the 2024 Annual General Meeting ("AGM") are now available on the Company's
website at www.avacta.com/investors/documents
(http://www.avacta.com/investors/documents) .

 

Copies of the Annual Report and Accounts and the Notice of the AGM have been
posted to registered shareholders who have elected to receive them in paper
form.

 

The Annual General Meeting will be held on Wednesday, 26 June 2024 at 10:30 AM
BST at Glaziers Hall, 9 Montague Close, London Bridge, London, SE1 9DD (the
"Venue").

 

The Venue has a capacity of approximately 200 people. Registered shareholders
have a right to attend the AGM.  In addition, the current expectation is that
the chair of the AGM will, at their discretion, permit beneficial shareholders
to attend in person. Shareholders (registered or beneficial) who propose to
attend the AGM in person are requested to pre-register their interest and, to
assist the Company in its preparation for the AGM, prove their shareholding by
emailing ICR Consilium at avacta@consilium-comms.com
(mailto:avacta@consilium-comms.com) by Friday, 21 June 2024. Any failure to
pre-register will not, of itself, preclude a registered shareholder from
attending the AGM in person (or by proxy).

 

Only registered shareholders who attend in person or by proxy will be able to
vote on the day. Details of how to submit a proxy vote are contained in the
Notice of the AGM.

 

The Company will provide a business update following the AGM, which will be
recorded and uploaded on the Company's website later that day for shareholders
who are not able to attend in person.

 

Early pre-registration to attend the AGM in person is recommended as the
Venue's capacity is limited (as referred to above) and, for non-registered
shareholders, registrations will be dealt with on a first come, first served
basis. All presentation materials will be made available on the website at the
end of the day and no new material information will be provided.

 

 

-Ends-

 

 

 

 

 

 

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                              Tel: +44 (0) 1904 21 7070

 Christina Coughlin, Chief Executive Officer                   www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)       Tel: +44 (0) 207 710 7600

 Nicholas Moore / Samira Essebiyea / Nick Harland / Ben Good   www.stifel.com (http://www.stifel.com/)

 Peel Hunt (Joint Broker)                                      Tel: +44 (0) 207 418 8900

 James Steel / Chris Golden / Patrick Birkholm                 www.peelhunt.com (http://www.peelhunt.com)

 ICR Consilium (Media and IR)                                  avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com/)

 

Avacta is a UK-based life sciences company focused on improving healthcare
outcomes through targeted cancer treatments and diagnostics.

 

Avacta Therapeutics is a clinical stage oncology biotech division harnessing
proprietary therapeutic platforms to develop novel, highly targeted cancer
drugs.

 

Avacta Diagnostics focuses on supporting healthcare professionals and
broadening access to diagnostics.

 

Avacta has two proprietary platforms, pre|CISION™ and Affimer(®).

 

The pre|CISION™ platform is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumor compared
with healthy tissues. The pre|CISION™ platform harnesses this tumor specific
protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™
antibody/Affimer® drug conjugates in the tumor microenvironment, reducing
systemic exposure and toxicity, allowing dosing to be optimised to deliver the
best outcomes for patients.

 

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of
doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in
safety and tolerability in clinical trials to date compared with standard
doxorubicin and preliminary signs of clinical activity in multiple patients.

 

To register for news alerts by email go
to www.avacta.com/Investors/Investor-news-email-alerts/
(https://avacta.com/Investors/Investor-news-email-alerts/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAWPUMPAUPCGQU